Every 10-Q that MIRA Pharmaceuticals, Inc. (MIRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MIRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MIRA filings page.
MIRA Pharmaceuticals, Inc. reported no revenues for the three and six months ended June 30, 2026 and remains a clinical-stage company. The net loss was $1.2 million for the quarter and $2.4 million year-to-date, compared with $1.5 million and $3.3 million in the prior-year periods, driven by sharply lower stock-based compensation and other general and administrative costs, partially offset by higher research and development spending.
Research and development expenses rose to $0.7 million for the quarter and $1.2 million year-to-date as the company advanced Ketamir-2 toward a planned Phase 2a CIPN trial in 2027 and progressed MIRA-55 and SKNY-1 through IND-enabling work. Cash was $3.6 million at June 30, 2026, with stockholders’ equity of $8.2 million and a related-party equity investment in Telomir Pharmaceuticals of $4.5 million.
Management expects existing cash to fund operations into at least the first quarter of 2027 but states that cash is insufficient to support operations for 12 months from issuance of these financial statements, raising substantial doubt about the company’s ability to continue as a going concern. On July 27, 2026, Nasdaq notified MIRA that its share price no longer meets the $1.00 minimum bid requirement, and the company is working to regain compliance within the allowed cure period.
MIRA Pharmaceuticals, Inc. reported a first-quarter 2026 net loss of $1,150,152 with no revenue, reflecting its clinical-stage focus on Ketamir-2, MIRA-55, and SKNY-1. Research and development expenses were $524,781 and general and administrative expenses were $578,698, both key drivers of the loss.
Cash was $4,815,031 and total assets were $9,463,736 as of March 31, 2026, with stockholders’ equity of $9,348,975 and minimal liabilities. The company recorded a $91,582 loss from its equity method investment in Telomir Pharmaceuticals. It used $1,201,283 of cash in operating activities in the quarter.
Management expects existing cash to fund operations into at least the first quarter of 2027, but states that current cash and cash equivalents are insufficient to support operations for 12 months from the financial statement issuance date. This, along with ongoing losses and funding needs for future trials, raises substantial doubt about MIRA’s ability to continue as a going concern absent additional financing.
MIRA Pharmaceuticals (Nasdaq: MIRA) filed its Q3 2025 report, highlighting a clinical-stage pipeline and a small acquisition that reshaped its balance sheet. The company closed the related‑party acquisition of SKNY Pharmaceuticals on September 29, issuing 19,755,738 shares and receiving 3,521,127 Telomir (TELO) shares recorded as short‑term investments.
Financials: Cash was $2.64 million as of September 30, 2025, with short‑term investments of $4.89 million. Stockholders’ equity rose to $7.55 million, up from $2.20 million at year‑end. Net loss was $1.14 million in Q3 and $4.46 million for the nine months. A $21.56 million deemed dividend was recorded from the SKNY share issuance. Operating cash outflow was $3.53 million year‑to‑date.
Capital and listing: The company sold 2.06 million shares via ATM during Q3 (net $2.71 million) and, subsequent to quarter‑end, raised about $3.7 million more through the ATM and received $0.59 million from CEO option exercises. MIRA regained compliance with Nasdaq’s equity rule; 41,876,087 shares were outstanding as of November 11, 2025. Going concern: The filing states substantial doubt about the ability to continue as a going concern without additional funding.
MIRA Pharmaceuticals, Inc. reported continued pre-revenue operations with material financing and compensation activity. For the six months ended June 30, 2025 the company used approximately $2.4 million of cash in operations and recorded a net loss of approximately $3.3 million. At June 30, 2025 the company reported stockholders' equity of approximately $0.6 million and had 19,069,315 (or similar reported) shares outstanding.
The filing discloses recent equity financings including an at-the-market offering that generated gross proceeds of approximately $2.0 million, separate block sales and other share issuances producing net proceeds around $0.3 million and $151,023. Management highlights a $5.0 million capital infusion referenced as strengthening the balance sheet. Significant equity-based compensation was granted in 2025, including options and 500,000 RSUs, and approximately $1.4 million of stock compensation expense was recorded year-to-date. The company notes cash in excess of FDIC limits of about $0.5 million and discloses related-party license and warrant arrangements.